Financials data is unavailable for this security.
View more
Year on year Bal Pharma Ltd grew revenues 11.51% from 3.04bn to 3.39bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 187.44% net income growth from 25.72m to 73.92m.
| Gross margin | 44.05% |
|---|---|
| Net profit margin | 2.22% |
| Operating margin | 6.29% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Bal Pharma Ltd increased its cash reserves by 182.15%, or 27.09m. The company earned 228.06m from its operations for a Cash Flow Margin of 6.72%. In addition the company used 188.91m on investing activities and also paid 12.06m in financing cash flows.
| Cash flow per share | 11.15 |
|---|---|
| Price/Cash flow per share | 11.45 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
